Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: A pilot study

International Journal of Dermatology

Volumn 53, Issue 4, 2014, Pages 503-509

  Erturan, Ijlal ^a   Köroǧlu, Banu Kale ^a   Adiloǧlu, Ali ^b   Ceyhan, Ali M ^a   Akkaya, Vahide B ^a   Tamer, Numan ^a   Başak, Pinar Y ^a   Korkmaz, Selma ^a   Ersoy, Ismail H ^a   Kilinç, Osman ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; HOMOCYSTEINE;

ADULT; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; CLINICAL INDICATOR; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER DEVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSORIASIS; SUBCLINICAL ATHEROSCLEROSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UNIVERSITY HOSPITAL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CD40 LIGAND; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; REGIONAL BLOOD FLOW; VASODILATION; YOUNG ADULT;

EID: 84896489541     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12397     Document Type: Article

References (35)

1. Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial. Eur J Dermatol 2010; 20: 329-333.
2. Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 1-6.
3. Turchin I, Adams SP. Dermacase. Psoriasis. Can Fam Physician 2006; 52: 1073-1080.
4. El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2010; 24: 661-666.
5. Dogra J. Oral azithromycin in extended dosage schedule for chronic, sub-clinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial. Int J Gen Med 2012; 5: 505-509.
6. Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009; 11: R51.
7. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
8. Karadag AS, Yavuz B, Ertugrul DT, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010; 49: 642-646.
9. Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
10. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, et al. Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X. Atherosclerosis 2010; 213: 637-641.
11. Pignatelli P, Sanguigni V, Lenti L, et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004; 110: 1326-1329.
12. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
13. Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003; 41: 275-279.
14. Martino F, Pignatelli P, Martino E, et al. Early increase of oxidative stress and soluble CD40L in children with hypercholesterolemia. J Am Coll Cardiol 2007; 49: 1974-1981.
15. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 2004; 38: 1500-1508.
16. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
17. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
18. Ohta Y, Hamada Y. In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology 2004; 209: 21-28.
19. Tobin AM, Hughes R, Hand EB, et al. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol 2010; 36: 19-23.
20. Cakmak SK, Gül U, Kiliç C, et al. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol 2009; 23: 300-303.
21. Spijkerman AM, Smulders YM, Kostense PJ, et al. Adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study. Arterioscler Thromb Vasc Biol 2005; 25: 778-784.
22. Ulusoy RE, Karabudak O, Yokusoglu M, et al. Noninvasive assessment of impaired endothelial function in psoriasis. Rheumatol Int 2010; 30: 479-483.
23. Daoussis D, Antonopoulos I, Andonopoulos AP, et al. Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis. Rheumatology 2007; 46: 227-231.
24. Myśliwiec H, Flisiak I, Baran A, et al. Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients. Folia Histochem Cytobiol 2012; 50: 75-79.
25. Ivandic BT, Spanuth E, Haase D, et al. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 2007; 53: 1231-1234.
26. Peng DQ, Zhao SP, Li YF, et al. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002; 319: 19-26.
27. Popkova TV, Panafidina TA, Aleksandrova EN, et al. Soluble CD40 ligand in systemic lupus erythematosus: link with atherosclerotic vascular affection. Ter Arkh 2008; 80: 37-41.
28. Richetta AG, Mattozzi C, Macaluso L, et al. Homocysteine plasmatic status in patients with psoriasis. Eur J Dermatol 2011; 21: 621-623.
29. Malerba M, Gisondi P, Radaeli A, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165-1169.
30. Liew SC, Das-Gupta E, Wong SF, et al. Association of methylentetraydrofolate reductase (MTHFR) 677 C > T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutr J 2012; 11: 1-7.
31. Kwok T, Chook P, Qiao M, et al. Vitamin B-12 supplementation improves arterial function in vegetarians with subnormal vitamin B-12 status. J Nutr Health Aging 2012; 16: 569-573.
32. Wustmann K, Klaey M, Burow A, et al. Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease. Cardiovasc Ther 2012; 30: 277-286.
33. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
34. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
35. Tam LS, Shang Q, Li EK, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008; 59: 1322-1331.